Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Human Genome Sciences, Inc. (HGSI) -- Ignore unavailable to you. Want to Upgrade?

To: Elmer who wrote (266)	4/27/1999 12:51:00 PM
From: Steven Rachbach	Read Replies (2) \| Respond to of 1127

David, You said, "Somehow I always thought that this company would just collect royalties from Big Pharma and live happily ever after." HGSI certainly has a different model than Incyte which will make their profits from collecting royalties. HGSI decided several years ago that it would be a vertically structured company that would test its own discovered drugs. Having just opened its own drug manufacturing facility, HGSI is well down this path. For sure, this approach is inherently more risky than Incyte's; but it's potentially much more rewarding as well. If MPIF, VEGF, and KEGF don't work out, HGSI would then have several options: merger partner, new financing, investment partner, etc. Regards, Steve Rachbach